Our product, ZetaMet™ (Zeta-BC-003) has thus far demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain, and stimulate targeted bone regeneration.
Zetagen has performed invitro human mesenchymal stem cells (hMSC), controlled and GLP preclinical studies substantiating these claims. These data have been submitted to Health Canada, the FDA and the TGA.